Stryker, Zimmer risk/reward remains favorable, says RW Baird Baird believes the risk/reward for both Stryker (SYK) and Zimmer Holdings (ZMH) remains favorable citing improving EBIT margins, earnings quality, and end markets, and undemanding valuations. Both are Outperform with Stryker's price target $68 and Zimmer's at $79.
News For SYK;ZMH From The Last 14 Days
Check below for free stories on SYK;ZMH the last two weeks.
On The Fly: Analyst Upgrade Summary Today's noteworthy upgrades include: Achillion (ACHN) upgraded to Buy from Hold at Deutsche Bank... CNOOC (CEO) upgraded to Neutral from Underperform at Credit Suisse... Dollar General (DG) upgraded to Buy from Neutral at Sterne Agee... Equity Residential (EQR) upgraded to Hold from Underperform at Jefferies... HMS Holdings (HMSY) upgraded to Overweight from Equal Weight at First Analysis... HP (HPQ) upgraded to Buy from Neutral at Monness Crespi... Halcon Resources (HK) upgraded to Buy from Hold at MLV & Co.... KapStone (KS) upgraded to Buy from Hold at Deutsche Bank... Sportsman's Warehouse (SPWH) upgraded at RW Baird... Westlake Chemical (WLK) upgraded to Neutral from Reduce at SunTrust... WisdomTree (WETF) upgraded to Neutral from Sell at Citigroup... Zimmer (ZMH) upgraded to Outperform from Market Perform at William Blair.
Zimmer upgraded to Outperform from Market Perform at William Blair William Blair upgraded Zimmer Holdings to Outperform citing the recent pullback in shares and its belief the proposed Biomet acquisition will close.